dna stain Notably the arrival reticulocyte count contributed

Notably, the arrival reticulocyte count contributed strongly to the predictive score, being significantly higher on day 1 than at steady state for 2°ACSs (272±88 vs 237±95, respectively p=0.006, n=33 paired values), while the VOC group\'s values were stable (p=0.98). Moreover, increased reticulocyte adhesion to activated endothelium and subendothelial matrix compounds (Hebbel, 1997; Swerlick et al., 1993) was mainly attributed to more membrane-adhesion molecules (El Nemer et al., 1998; Cartron and Elion, 2008), some of which disappear on mature RBCs, e.g., α4β1 or CD36 (Swerlick et al., 1993; Browne and Hebbel, 1996; Joneckis et al., 1993), and to functional signaling pathways more active in reticulocytes than mature RBCs (Bartolucci et al., 2010; Limbird et al., 1980). Leukocytes are the other major score component. Their increase during VOCs has been proven; (Ballas et al., 1988) however, they were less able discriminate between ACS and VOC than reticulocytes. Leukocytes are known to be an independent factor predictive of SCD-associated death (Platt et al., 1994). Reported results demonstrated enhanced leukocyte adhesion to SS RBCs (Chaar et al., 2010) and vascular endothelium (Turhan et al., 2002), and their subsequent leukocyte participation in vaso-occlusion (Belcher et al., 2000; Hidalgo et al., 2009). Pertinently, hydroxyurea did not modify the score, perhaps because patients taking it have lower reticulocyte and leukocyte counts. Hence, a reticulocyte or leukocyte rise under it would probably discriminate better between groups than without such increases. Furthermore, the comparable percentages of hydroxyurea-treated patients in our two groups indicate that, when treated patients develop severe VOCs requiring hospitalization, their risk of worsening is comparable to that of untreated patients, which should not be confused with hydroxyurea\'s protective effect against ACS and VOC (Charache et al., 1995). Because the hydroxyurea dose was not considered in this study, we could not exclude a difference according to its dose. Morphine consumption on hospital days 1, 2 and 4 did not differ between groups, thereby excluding its possible effect on ACS appearance, in dna stain to previous hypotheses (Kopecky et al., 2004; Buchanan et al., 2005). Our study was homogenous because of its monocenter design with the same physicians, biologists and guidelines for all patients. Our results enabled a score to be built that could bring new perspectives to SCD management, but remains to be validated in other centers and countries, and tested on pediatric populations, before concluding as to its usefulness. In conclusion, a score predicting ACS as of Emergency-Department arrival for VOC, based on reticulocyte and leukocyte counts, hemoglobin and S±P CPS, is simple enough to be easily applied and could change VOC therapeutic perspectives.
Authors Contributions
Disclosure of Conflicts of Interest
Acknowledgments
Introduction Live attenuated vaccines including measles vaccine (MV), BCG, oral polio vaccine (OPV) and smallpox vaccine have beneficial effects on survival beyond protection against the targeted infections (Aaby et al., 1995; Kristensen et al., 2000; Aaby et al., 2010; Aaby et al., 2011; Biering-Sørensen et al., 2012; Lund et al., 2015; Sørup et al., 2014). Hence, these vaccines induce some form of nonspecific immunity. For example, two doses of MV at 4.5 and 9months reduced all-cause mortality between 4.5 and 36months by 30% (95% CI: 6–48%) compared with a single dose at 9months (Aaby et al., 2010). WHO recently reviewed the evidence for nonspecific effects (NSEs) of BCG, MV and diphtheria-tetanus-pertussis (DTP) vaccine and concluded that BCG and MV were associated with beneficial effects in the range of halving mortality (Higgins et al., 2014; Strategic Advisory Group of Experts on Immunization, 2014). Measles vaccination in presence of maternal antibodies is associated with lower antibody responses. However, the beneficial NSEs of early MV were particularly strong if the initial MV was administered in the presence of maternal measles antibody (Aaby et al., 2010; Benn et al., 1997; Aaby et al., 2014). We speculated that NSEs are induced more strongly with pre-existing immunity (Aaby et al., 2014). If this is the case, then one would expect to see strong beneficial NSEs of live attenuated vaccines when given to children who have specific immunity from a previous vaccination or even in children who already had the target disease.